Longevity of immunity following COVID-19 vaccination: a comprehensive review of the currently approved vaccines
It is unknown how long the immunity following COVID-19 vaccination lasts. The current systematic review provides a perspective on the persistence of various antibodies for available vaccines.Both the BNT162b2 and the mRNA-1273 induce the production of IgA antibodies, reflecting the possible preventi...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-11-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2022.2037384 |
| _version_ | 1797673265953505280 |
|---|---|
| author | Elham Jamshidi Amirhossein Asgary Paria Shafiekhani Yasaman Khajeamiri Kawthar Mohamed Hadi Esmaily Sahand Jamal Rahi Nahal Mansouri |
| author_facet | Elham Jamshidi Amirhossein Asgary Paria Shafiekhani Yasaman Khajeamiri Kawthar Mohamed Hadi Esmaily Sahand Jamal Rahi Nahal Mansouri |
| author_sort | Elham Jamshidi |
| collection | DOAJ |
| description | It is unknown how long the immunity following COVID-19 vaccination lasts. The current systematic review provides a perspective on the persistence of various antibodies for available vaccines.Both the BNT162b2 and the mRNA-1273 induce the production of IgA antibodies, reflecting the possible prevention of the asymptomatic spread. The mRNA-1273 vaccineʻs antibodies were detectable until 6 months, followed by the AZD1222, 3 months, the Ad26.COV2.S and the BNT162b2 vaccines within 2 months.The BNT162b2 produced anti-spike IgGs 11 days after the first dose and peaked at day 21, whereas the AZD1222 induced a neutralizing effect 22 days after the first dose.These vaccines induce T-cell mediated immune responses too. Each one of the AZD1222, Ad26.COV2.S, mRNA-1273 mediates T-cell response immunity at days 14-22, 15, and 43 after the first dose, respectively. Whereas for the BNT162b1 and BNT162b2 vaccines, T-cell immunity is induced 7 days and 12 weeks after the booster dose, respectively. |
| first_indexed | 2024-03-11T21:42:02Z |
| format | Article |
| id | doaj.art-c04ac057df5c44b298e657e0e8e842cb |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T21:42:02Z |
| publishDate | 2022-11-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-c04ac057df5c44b298e657e0e8e842cb2023-09-26T12:57:38ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2022-11-0118510.1080/21645515.2022.20373842037384Longevity of immunity following COVID-19 vaccination: a comprehensive review of the currently approved vaccinesElham Jamshidi0Amirhossein Asgary1Paria Shafiekhani2Yasaman Khajeamiri3Kawthar Mohamed4Hadi Esmaily5Sahand Jamal Rahi6Nahal Mansouri7Shahid Beheshti University of Medical SciencesUniversity of TehranShahid Beheshti University of Medical SciencesShahid Beheshti University of Medical SciencesTehran University of Medical SciencesShahid Beheshti University of Medical SciencesÉcole polytechnique fédérale de Lausanne (EPFL)University of Lausanne (UNIL)It is unknown how long the immunity following COVID-19 vaccination lasts. The current systematic review provides a perspective on the persistence of various antibodies for available vaccines.Both the BNT162b2 and the mRNA-1273 induce the production of IgA antibodies, reflecting the possible prevention of the asymptomatic spread. The mRNA-1273 vaccineʻs antibodies were detectable until 6 months, followed by the AZD1222, 3 months, the Ad26.COV2.S and the BNT162b2 vaccines within 2 months.The BNT162b2 produced anti-spike IgGs 11 days after the first dose and peaked at day 21, whereas the AZD1222 induced a neutralizing effect 22 days after the first dose.These vaccines induce T-cell mediated immune responses too. Each one of the AZD1222, Ad26.COV2.S, mRNA-1273 mediates T-cell response immunity at days 14-22, 15, and 43 after the first dose, respectively. Whereas for the BNT162b1 and BNT162b2 vaccines, T-cell immunity is induced 7 days and 12 weeks after the booster dose, respectively.http://dx.doi.org/10.1080/21645515.2022.2037384covid-19vaccinessars-cov-2immunogenicityhumoral immunitycell-mediated immunityantibody persistencelong-term protectionlong-term immunity |
| spellingShingle | Elham Jamshidi Amirhossein Asgary Paria Shafiekhani Yasaman Khajeamiri Kawthar Mohamed Hadi Esmaily Sahand Jamal Rahi Nahal Mansouri Longevity of immunity following COVID-19 vaccination: a comprehensive review of the currently approved vaccines Human Vaccines & Immunotherapeutics covid-19 vaccines sars-cov-2 immunogenicity humoral immunity cell-mediated immunity antibody persistence long-term protection long-term immunity |
| title | Longevity of immunity following COVID-19 vaccination: a comprehensive review of the currently approved vaccines |
| title_full | Longevity of immunity following COVID-19 vaccination: a comprehensive review of the currently approved vaccines |
| title_fullStr | Longevity of immunity following COVID-19 vaccination: a comprehensive review of the currently approved vaccines |
| title_full_unstemmed | Longevity of immunity following COVID-19 vaccination: a comprehensive review of the currently approved vaccines |
| title_short | Longevity of immunity following COVID-19 vaccination: a comprehensive review of the currently approved vaccines |
| title_sort | longevity of immunity following covid 19 vaccination a comprehensive review of the currently approved vaccines |
| topic | covid-19 vaccines sars-cov-2 immunogenicity humoral immunity cell-mediated immunity antibody persistence long-term protection long-term immunity |
| url | http://dx.doi.org/10.1080/21645515.2022.2037384 |
| work_keys_str_mv | AT elhamjamshidi longevityofimmunityfollowingcovid19vaccinationacomprehensivereviewofthecurrentlyapprovedvaccines AT amirhosseinasgary longevityofimmunityfollowingcovid19vaccinationacomprehensivereviewofthecurrentlyapprovedvaccines AT pariashafiekhani longevityofimmunityfollowingcovid19vaccinationacomprehensivereviewofthecurrentlyapprovedvaccines AT yasamankhajeamiri longevityofimmunityfollowingcovid19vaccinationacomprehensivereviewofthecurrentlyapprovedvaccines AT kawtharmohamed longevityofimmunityfollowingcovid19vaccinationacomprehensivereviewofthecurrentlyapprovedvaccines AT hadiesmaily longevityofimmunityfollowingcovid19vaccinationacomprehensivereviewofthecurrentlyapprovedvaccines AT sahandjamalrahi longevityofimmunityfollowingcovid19vaccinationacomprehensivereviewofthecurrentlyapprovedvaccines AT nahalmansouri longevityofimmunityfollowingcovid19vaccinationacomprehensivereviewofthecurrentlyapprovedvaccines |